BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol 2019;10:1282. [PMID: 31231391 DOI: 10.3389/fimmu.2019.01282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
2 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
3 Shawky S, Safouh H, Gamal M, Abbas MM, Aboul-Enein A, Sawai T, Fahmy Y, Selim H. Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome. Int J Nephrol 2021;2021:6904858. [PMID: 34840826 DOI: 10.1155/2021/6904858] [Reference Citation Analysis]
4 Matrat L, Bacchetta J, Ranchin B, Tanné C, Sellier-Leclerc AL. Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil? Pediatr Nephrol 2021;36:1647-50. [PMID: 33774745 DOI: 10.1007/s00467-021-05025-8] [Reference Citation Analysis]
5 Iorember F, Nayak A. Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring. Pediatr Nephrol 2021;36:1365-75. [PMID: 32529325 DOI: 10.1007/s00467-020-04652-x] [Reference Citation Analysis]
6 Zhou D, Tan Y, Liu X, Tang L, Wang H, Shen J, Wang W, Zhuang L, Tao J, Su J, Gong T, Liu X, Liang P, Yu F, Zhao M. Patient-specific iPSC-derived endothelial cells reveal aberrant p38 MAPK signaling in atypical hemolytic uremic syndrome. Stem Cell Reports 2021:S2213-6711(21)00377-5. [PMID: 34388364 DOI: 10.1016/j.stemcr.2021.07.011] [Reference Citation Analysis]
7 Wu X, Szarzanowicz A, Garba A, Schaefer B, Waz WR. Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review. Cureus 2021;13:e19476. [PMID: 34912617 DOI: 10.7759/cureus.19476] [Reference Citation Analysis]
8 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Hanna RM, Hou J, Hasnain H, Arman F, Selamet U, Wilson J, Olanrewaju S, Zuckerman JE, Barsoum M, Yabu JM, Kurtz I. Diverse Clinical Presentations of C3 Dominant Glomerulonephritis. Front Med (Lausanne) 2020;7:293. [PMID: 32695788 DOI: 10.3389/fmed.2020.00293] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Minato S, Iijima H, Nakao H, Nishi K, Hidaka Y, Inoue N, Kubota M, Ishiguro A. Anti-complement factor H (CFH) antibodies and a novel CFH gene mutation in an atypical hemolytic uremic syndrome patient with complement activation of the classical pathway. Immunol Med 2021;:1-4. [PMID: 33784485 DOI: 10.1080/25785826.2021.1905303] [Reference Citation Analysis]
11 Khandelwal P, Bagga A. Guidelines on Hemolytic Uremic Syndrome by Indian Society of Pediatric Nephrology: Key Messages. Indian Pediatr 2020;57:744-7. [DOI: 10.1007/s13312-020-1920-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A. Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety. J Clin Apher 2019;34:555-62. [PMID: 31173399 DOI: 10.1002/jca.21711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]